Propranolol plus immunotherapy and chemo before bladder cancer surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests adding a blood pressure medication (propranolol) to a combination of immunotherapy (tislelizumab) and chemotherapy before surgery for bladder cancer that has spread to lymph nodes. It aims to see if this can help shrink the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer (urothelial type) that has spread to nearby lymph nodes but not to other organs.
- You are 18 or older and willing to follow the study plan.
- You are able to do normal daily activities (ECOG score 0 or 1) or have reasons you cannot take standard cisplatin chemotherapy.
- Your blood pressure is normal (between 110-140 systolic) without using blood pressure medicine.
- You have not had prior treatment with immunotherapy drugs (like PD-1 or PD-L1 inhibitors) or other similar therapies.
- You are not currently taking beta-blocker medication (like atenolol or metoprolol) or can safely stop it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
This trial tests a combination of two drugs (Tislelizumab and Palbociclib) given before bladder removal surgery. It is for people with bladder cancer that has a specific genetic change and who cannot take the standard chemotherapy cisplatin.
This trial tests a new drug combination for advanced bladder or urinary tract cancer that has not been treated before. The study compares a standard chemotherapy plus immunotherapy with and without an extra drug that may reduce side effects.
This trial tests a new combination of two drugs—9MW2821 (an antibody-drug conjugate) and Toripalimab (an immunotherapy)—given before and after surgery for muscle-invasive or high-risk urothelial cancer that has not spread. The goal is to see if this combined treatment can improve outcomes.
This trial tests if taking probiotics can help people with advanced bladder or urinary tract cancer that has spread. It's for those who have already tried immunotherapy. The goal is to see if probiotics can improve treatment outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (etoposide and cisplatin) given before surgery for a rare, aggressive type of bladder cancer called neuroendocrine carcinoma. The goal is to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Lymph Node Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.